Company intelligence / Profile preview
Axcella
Cambridge, MA, USAaxcellatx.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Phase 2
01
Overview
Lead clinical results showed promise in reducing risk of overt hepatic encephalopathy recurrence and treating symptoms of long COVID fatigue; the company also received a patent related to long COVID treatment. However, the company was dissolved by end of December 2023.
- Therapeutic areas
- GastroenterologyHematologyInfectious Diseases
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of last available data.
Beyond the preview
Go deeper on Axcella.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axcella.